Literatur
- 1
Alizadeh A A, Eisen M B, Davis R E. et al .
Distinct types
of diffuse large B-cell lymphoma identified by gene expression profiling.
Nature.
2000;
403
503-511
- 2
Ashley E A, Butte A J, Wheeler M T. et al .
Clinical assessment incorporating
a personal genome.
Lancet.
2010;
375
1525-1535
- 3
Asselah T, Bieche I, Laurendeau I. et al .
Liver gene expression signature of mild
fibrosis in patients with chronic hepatitis C.
Gastroenterology.
2005;
129
2064-2075
- 4
Bild A H, Yao G, Chang J T. et al .
Oncogenic pathway signatures in human cancers
as a guide to targeted therapies.
Nature.
2006;
439
353-357
- 5
Blum H E.
[Molecular medicine – personalized medicine.
Principles and state-of-the-art].
Dtsch Med Wochenschr.
2005;
130
1568-1572
- 6
Boyault S, Rickman D S, de Reynies A. et al .
Transcriptome classification
of HCC is related to gene alterations and to new therapeutic targets.
Hepatology.
2007;
45
42-52
- 7
Caskey C T.
Using genetic diagnosis to determine individual therapeutic
utility.
Annu Rev Med.
2010;
61
1-15
- 8
Chang J C, Wooten E C, Tsimelzon A. et al .
Gene expression profiling for the prediction
of therapeutic response to docetaxel in patients with breast cancer.
Lancet.
2003;
362
362-369
- 9
Chen H Y, Yu S L, Chen C H. et al .
A five-gene signature and clinical outcome
in non-small-cell lung cancer.
N Engl J Med.
2007;
356
11-20
- 10
Ciardiello F, Tortora G.
EGFR antagonists in cancer
treatment.
N Engl J Med.
2008;
358
1160-1174
- 11
Cunningham D, Atkin W, Lenz H J. et al .
Colorectal cancer.
Lancet.
2010;
375
1030-1047
- 12
Di Nicolantonio F, Martini M, Molinari F. et al .
Wild-type BRAF is required for response
to panitumumab or cetuximab in metastatic colorectal cancer.
J
Clin Oncol.
2008;
26
5705-5712
- 13
Dragani T A.
Risk of HCC: genetic heterogeneity and complex genetics.
J
Hepatol.
2010;
52
252-257
- 14
Dufour J F, Johnson P.
Liver cancer: from molecular
pathogenesis to new therapies: summary of the EASL single topic
conference.
J Hepatol.
2010;
52
296-304
- 15
Dunckley T, Huentelman M J, Craig D W. et al .
Whole-genome analysis of
sporadic amyotrophic lateral sclerosis.
N Engl J Med.
2007;
357
775-788
- 16
Fallik D, Borrini F, Boige V. et al .
Microsatellite instability is a predictive
factor of the tumor response to irinotecan in patients with advanced
colorectal cancer.
Cancer Res.
2003;
63
5738-5744
- 17
Fellay J, Thompson A J, Ge D. et al .
ITPA gene variants protect against anaemia
in patients treated for chronic hepatitis C.
Nature.
2010;
464
405-408
- 18
Goldstein D B.
Common genetic variation and human traits.
N Engl
J Med.
2009;
360
1696-1698
- 19
Hafler D A, Compston A, Sawcer S. et al .
Risk alleles for multiple sclerosis identified
by a genomewide study.
N Engl J Med.
2007;
357
851-862
- 20
Herbst R S, Lippman S M.
Molecular
signatures of lung cancer – toward personalized therapy.
N Engl J Med.
2007;
356
76-78
- 21
Hidalgo M.
Pancreatic cancer.
N Engl J Med.
2010;
362
1605-1617
- 22
Hood L, Heath J R, Phelps M E, Lin B.
Systems biology
and new technologies enable predictive and preventative medicine.
Science.
2004;
306
640-643
- 23
Huang E, Cheng S H, Dressman H. et al .
Gene expression predictors of breast cancer
outcomes.
Lancet.
2003;
361
1590-1596
- 24
Iizuka N, Oka M, Yamada-Okabe H. et al .
Oligonucleotide microarray for prediction
of early intrahepatic recurrence of hepatocellular carcinoma after
curative resection.
Lancet.
2003;
361
923-929
- 25
International HapMap Consortium .
A haplotype map of the human genome.
Nature.
2005;
437
1299-1320
- 26
Ji J, Shi J, Budhu A. et
al .
MicroRNA expression, survival, and response to
interferon in liver cancer.
N Engl J Med.
2009;
361
1437-1447
- 27
Karapetis C S, Khambata-Ford S, Jonker D J. et al .
K-ras mutations and benefit
from cetuximab in advanced colorectal cancer.
N Engl J
Med.
2008;
359
1757-1765
- 28
Kraft P, Hunter D J.
Genetic risk prediction – are
we there yet?.
N Engl J Med.
2009;
360
1701-1703
- 29
Lander E S, Linton L M, Birren B. et al .
Initial sequencing and analysis of the
human genome.
Nature.
2001;
409
860-921
- 30
Lee J S, Thorgeirsson S S.
Comparative
and integrative functional genomics of HCC.
Oncogene.
2006;
25
3801-3809
- 31
Lenz G, Wright G, Dave S S. et al .
Stromal gene signatures in large-B-cell
lymphomas.
N Engl J Med.
2008;
359
2313-2323
- 32
Liu R, Wang X, Chen G Y. et al .
The prognostic role of a gene signature
from tumorigenic breast-cancer cells.
N Engl J Med.
2007;
356
217-226
- 33
Luo J H, Ren B, Keryanov S. et al .
Transcriptomic and genomic analysis of
human hepatocellular carcinomas and hepatoblastomas.
Hepatology.
2006;
44
1012-1024
- 34
Manolio T A, Brooks L D, Collins F S.
A HapMap harvest of insights into the genetics
of common disease.
J Clin Invest.
2008;
118
1590-1605
- 35
Manolio T A, Collins F S.
The HapMap
and genome-wide association studies in diagnosis and therapy.
Annu Rev Med.
2009;
60
443-456
- 36
Marcolongo M, Young B, Dal Pero F. et al .
A seven-gene signature (cirrhosis risk
score) predicts liver fibrosis progression in patients with initially
mild chronic hepatitis C.
Hepatology.
2009;
50
1038-1044
- 37
Massague J.
Sorting out breast-cancer gene signatures.
N Engl
J Med.
2007;
356
294-297
- 38
Mayer R J.
Targeted therapy for advanced colorectal cancer – more
is not always better.
N Engl J Med.
2009;
360
623-625
- 39
Messersmith W A, Ahnen D J.
Targeting
EGFR in colorectal cancer.
N Engl J Med.
2008;
359
1834-1836
- 40
Mok T S, Wu Y L, Thongprasert S. et al .
Gefitinib or carboplatin-paclitaxel in
pulmonary adenocarcinoma.
N Engl J Med.
2009;
361
947-957
- 41
Petersen K F, Dufour S, Hariri A. et al .
Apolipoprotein C3 gene variants in nonalcoholic
fatty liver disease.
N Engl J Med.
2010;
362
1082-1089
- 42
Pham M X, Teuteberg J J, Kfoury A G. et al .
Gene-Expression Profiling
for Rejection Surveillance after Cardiac Transplantation.
N
Engl J Med.
2010;
362
1890-1900
- 43
Pineau P, Volinia S, McJunkin K. et al .
miR-221 overexpression contributes to liver
tumorigenesis.
Proc Natl Acad Sci U S A.
2010;
107
264-269
- 44
Pritchard K I, Shepherd L E, O’Malley F P. et al .
HER2 and responsiveness
of breast cancer to adjuvant chemotherapy.
N Engl J Med.
2006;
354
2103-2111
- 45
Rauch A, Kutalik Z, Descombes P. et al .
Genetic variation in IL28B is associated
with chronic hepatitis C and treatment failure: a genome-wide association
study.
Gastroenterology.
2010;
138
1338-1345, 1345 e1331 – 1337
- 46
Rosenzweig A.
Scanning the genome for coronary risk.
N Engl J Med.
2007;
357
497-499
- 47
Samani N J, Erdmann J, Hall A S. et al .
Genomewide association analysis of coronary
artery disease.
N Engl J Med.
2007;
357
443-453
- 48
Samani N J, Tomaszewski M, Schunkert H.
The personal genome – the future of personalised medicine?.
Lancet.
2010;
375
1497-1498
- 49
Sotiriou C, Pusztai L.
Gene-expression signatures
in breast cancer.
N Engl J Med.
2009;
360
790-800
- 50
Stefansson H, Rye D B, Hicks A. et al .
A genetic risk factor for periodic limb
movements in sleep.
N Engl J Med.
2007;
357
639-647
- 51
Steidl C, Lee T, Shah S P. et al .
Tumor-associated macrophages and survival
in classic Hodgkin’s lymphoma.
N Engl J Med.
2010;
362
875-885
- 52
Suppiah V, Moldovan M, Ahlenstiel G. et al .
IL28B is associated with response to chronic hepatitis
C interferon-alpha and ribavirin therapy.
Nat Genet.
2009;
41
1100-1104
- 53
Tanabe K K, Lemoine A, Finkelstein D M. et al .
Epidermal growth factor
gene functional polymorphism and the risk of hepatocellular carcinoma
in patients with cirrhosis.
JAMA.
2008;
299
53-60
- 54
Tanaka Y, Nishida N, Sugiyama M. et al .
Genome-wide association of IL28B with response to
pegylated interferon-alpha and ribavirin therapy for chronic hepatitis
C.
Nat Genet.
2009;
41
1105-1109
- 55
The International HapMap Project.
Nature.
2003;
426
789-796
- 56
Thomas D L, Thio C L, Martin M P. et al .
Genetic variation in IL28B
and spontaneous clearance of hepatitis C virus.
Nature.
2009;
461
798-801
- 57
Thorgeirsson S S, Lee J S, Grisham J W.
Molecular prognostication of liver
cancer: end of the beginning.
J Hepatol.
2006;
44
798-805
- 58
Tol J, Koopman M, Cats A. et
al .
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal
cancer.
N Engl J Med.
2009;
360
563-572
- 59
Van Cutsem E, Kohne C H, Hitre E. et al .
Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer.
N Engl J Med.
2009;
360
1408-1417
- 60
Van Cutsem E. et al .
Abstr. LBA4509.
J Clin Oncol.
2009;
27
18s
- 61
van de Vijver M J, He Y D, van’t
Veer L J. et al .
A gene-expression
signature as a predictor of survival in breast cancer.
N
Engl J Med.
2002;
347
1999-2009
- 62
Venter J C, Adams M D, Myers E W. et al .
The sequence of the human
genome.
Science.
2001;
291
1304-1351
- 63
Villanueva A, Minguez B, Forner A, Reig M, Llovet J M.
Hepatocellular carcinoma: novel molecular approaches for diagnosis,
prognosis, and therapy.
Annu Rev Med.
2010;
61
317-328
- 64
Wacholder S, Hartge P, Prentice R. et al .
Performance of common genetic variants
in breast-cancer risk models.
N Engl J Med.
2010;
362
986-993
- 65
Wen H, Yoo S S, Kang J. et al .
A new NMR-based metabolomics approach for
the diagnosis of biliary tract cancer.
J Hepatol.
2010;
52
228-233
- 66
Xiong Y, Fang J H, Yun J P. et al .
Effects of microRNA-29 on apoptosis, tumorigenicity,
and prognosis of hepatocellular carcinoma.
Hepatology.
2010;
51
836-845
- 67
Yanagisawa K, Shyr Y, Xu B J. et al .
Proteomic patterns of tumour subsets in
non-small-cell lung cancer.
Lancet.
2003;
362
433-439
- 68
Yao J, Liang L, Huang S. et
al .
MicroRNA-30d promotes tumor invasion and metastasis
by targeting Galphai2 in hepatocellular carcinoma.
Hepatology.
2010;
51
846-856
Prof. Dr. med. Dr. h. c. mult. H. E. Blum
Abteilung Innere
Medizin II, Medizinische Universitätsklinik
Hugstetter
Straße 55
79106 Freiburg
Phone: 0761/270
3404
Fax: 0761/270 3610
Email: hubert.blum@uniklinik-freiburg.de
